IL313901A - Compositions and methods for treating huntington's disease - Google Patents
Compositions and methods for treating huntington's diseaseInfo
- Publication number
- IL313901A IL313901A IL313901A IL31390124A IL313901A IL 313901 A IL313901 A IL 313901A IL 313901 A IL313901 A IL 313901A IL 31390124 A IL31390124 A IL 31390124A IL 313901 A IL313901 A IL 313901A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- subject
- antibody
- seq
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295213P | 2021-12-30 | 2021-12-30 | |
| US202263349305P | 2022-06-06 | 2022-06-06 | |
| PCT/US2022/082523 WO2023130001A1 (en) | 2021-12-30 | 2022-12-29 | Compositions and methods for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313901A true IL313901A (en) | 2024-08-01 |
Family
ID=87000332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313901A IL313901A (en) | 2021-12-30 | 2022-12-29 | Compositions and methods for treating huntington's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250074973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4457244A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240126863A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022425559A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313901A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008273A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023130001A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) * | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| EP3380518B1 (en) * | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2022
- 2022-12-29 US US18/725,580 patent/US20250074973A1/en active Pending
- 2022-12-29 JP JP2024539560A patent/JP2025503545A/ja active Pending
- 2022-12-29 AU AU2022425559A patent/AU2022425559A1/en active Pending
- 2022-12-29 EP EP22917557.5A patent/EP4457244A4/en active Pending
- 2022-12-29 IL IL313901A patent/IL313901A/en unknown
- 2022-12-29 KR KR1020247023399A patent/KR20240126863A/ko active Pending
- 2022-12-29 MX MX2024008273A patent/MX2024008273A/es unknown
- 2022-12-29 WO PCT/US2022/082523 patent/WO2023130001A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4457244A4 (en) | 2026-01-07 |
| EP4457244A1 (en) | 2024-11-06 |
| US20250074973A1 (en) | 2025-03-06 |
| JP2025503545A (ja) | 2025-02-04 |
| AU2022425559A1 (en) | 2024-07-04 |
| MX2024008273A (es) | 2024-07-19 |
| KR20240126863A (ko) | 2024-08-21 |
| WO2023130001A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Talbot et al. | CCR2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis | |
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| Khalil et al. | Follicular mucinosis: a review | |
| Kremer et al. | A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone | |
| Fleischmann et al. | Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs | |
| Loretelli et al. | The IL-8-CXCR1/2 axis contributes to diabetic kidney disease | |
| Brakemeier et al. | Experience with belatacept rescue therapy in kidney transplant recipients | |
| Kebriaei et al. | Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation | |
| JP2022534020A (ja) | Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| Kumar et al. | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial | |
| JP2020535149A5 (cg-RX-API-DMAC7.html) | ||
| Egan et al. | Chronic myelogenous leukemia | |
| Utomo et al. | Macrophage phenotypes and monocyte subsets after destabilization of the medial meniscus in mice | |
| JP2019528306A5 (cg-RX-API-DMAC7.html) | ||
| US20240401045A1 (en) | Angiotensinogen-modulating compositions and methods of use thereof | |
| Horinouchi et al. | Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial | |
| IL313901A (en) | Compositions and methods for treating huntington's disease | |
| Rosen et al. | Pegylated asparaginase in combination with high‐dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study | |
| CO2023001922A2 (es) | Composiciones y métodos para tratar trastornos asociados a mutaciones de pérdida de función en scn2a | |
| WO2023192630A2 (en) | Angiotensinogen-modulating compositions and methods of use thereof | |
| WO2025024283A1 (en) | Coagulation factor xi-modulating compositions and methods of use thereof | |
| Steverding et al. | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine | |
| Mueller et al. | Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study | |
| Kraker et al. | Treatment options for necrotizing scleritis in rheumatoid arthritis patients | |
| EP4028425A1 (en) | Methods of treatment using omalizumab |